Key result
Percutaneous mitral valve repair using the Mitraclip system in high-risk patients achieved an 88% primary safety endpoint and 78% acute procedural success, with a 1-year MACE rate of 41%.
Why the study?
Does percutaneous edge-to-edge mitral valve repair improve clinical outcomes in high surgical risk patients with symptomatic severe mitral regurgitation?
Observational (n=41)
Yes
Does percutaneous edge-to-edge mitral valve repair improve clinical outcomes in high surgical risk patients with symptomatic severe mitral regurgitation?
Percutaneous edge-to-edge mitral valve repair is feasible and safe in high-risk patients with functional MR, but careful patient selection is crucial as MACE rates are high in those with severely reduced LVEF.
No takes yet. Share an insight, caveat, or question.
High MACE rates warrant careful selection in low-LVEF patients; leaves open outcome benefit versus medical therapy in trials.
Vandendriessche et al. (2014) conducted an observational in symptomatic severe mitral regurgitation (n=41). Mitraclip (percutaneous edge-to-edge mitral valve repair) was evaluated on Primary safety end point. Percutaneous mitral valve repair using the Mitraclip system in high-risk patients achieved an 88% primary safety endpoint and 78% acute procedural success, with a 1-year MACE rate of 41%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: